Related Experiment Video

Updated: May 8, 2026

Induction of Intestinal Inflammation by Adoptive Transfer of CBir1 TCR Transgenic CD4+ T Cells to Immunodeficient Mice
07:34

Induction of Intestinal Inflammation by Adoptive Transfer of CBir1 TCR Transgenic CD4+ T Cells to Immunodeficient Mice

Published on: December 16, 2021

Combined blockade of IL-17A and IL-17F may prevent the development of experimental colitis

Leon P McLean1, Raymond K Cross, Terez Shea-Donohue

  • 1University of Maryland School of Medicine, Department of Medicine, Division of Gastroenterology & Hepatology, MD, USA.

Immunotherapy
|September 4, 2013
PubMed

Insights

Blocking both Interleukin-17A (IL-17A) and Interleukin-17F (IL-17F) effectively reduces experimental colitis. This combined blockade may offer a new therapeutic strategy for inflammatory bowel disease, unlike targeting IL-17A alone.

Area of Science:

  • Immunology
  • Gastroenterology
  • Inflammation Research

Background:

  • T helper 17 (Th17) cells play a significant role in the pathogenesis of colitis.
  • Interleukin-17A (IL-17A) and Interleukin-17F (IL-17F) are key effector cytokines produced by Th17 cells.
  • Previous studies targeting IL-17A alone for inflammatory bowel disease (IBD) have shown limited efficacy and increased adverse events.

Purpose of the Study:

  • To investigate the therapeutic potential of simultaneously blocking both IL-17A and IL-17F in a model of experimental colitis.
  • To determine if combined blockade is superior to targeting either cytokine individually for attenuating colitis development.

Main Methods:

  • Utilized a T-cell transfer model of experimental colitis.
  • Administered blockade of both IL-17A and IL-17F.
  • Compared the effects of combined blockade with blockade of single cytokines or placebo.

Main Results:

  • Combined blockade of IL-17A and IL-17F significantly attenuated the development of experimental colitis.
  • Targeting either IL-17A or IL-17F alone did not produce the same level of therapeutic benefit.
  • These findings suggest a synergistic role for IL-17A and IL-17F in colitis pathogenesis.

Conclusions:

  • Simultaneous blockade of IL-17A and IL-17F presents a promising therapeutic strategy for inflammatory bowel disease.
  • This approach may overcome the limitations observed with targeting IL-17A alone.
  • Further clinical investigation is warranted to evaluate combined IL-17A and IL-17F blockade in IBD patients.

More Related Videos

Induction of Murine Intestinal Inflammation by Adoptive Transfer of Effector CD4+CD45RBhigh T Cells into Immunodeficient Mice08:37

Induction of Murine Intestinal Inflammation by Adoptive Transfer of Effector CD4+CD45RBhigh T Cells into Immunodeficient Mice

Published on: April 21, 2015

Isolation and Th17 Differentiation of Naïve CD4 T Lymphocytes12:59

Isolation and Th17 Differentiation of Naïve CD4 T Lymphocytes

Published on: September 26, 2013

Related Concept Videos

T Cell Types and Functions01:24

T Cell Types and Functions

When T cells with CD4 markers are activated, they give rise to two types of effector cells: helper T cells and regulatory T cells. Meanwhile, T cells with CD8 markers differentiate into effector cytotoxic T cells. The differentiation of CD4 T cells into helper T cell subsets, such as Th1, Th2, and Th17 cells, is dependent on the antigen type, antigen-presenting cell, and regulatory cytokines.
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
Inflammatory Bowel Disease III: Crohn's Disease01:25

Inflammatory Bowel Disease III: Crohn's Disease

Crohn’s disease is a chronic, relapsing form of inflammatory bowel disease characterized by segmental, transmural inflammation that can affect any part of the gastrointestinal tract. Its pathogenesis arises from a combination of genetic susceptibility, environmental exposures, epithelial barrier dysfunction, and immune dysregulation. Together, these factors lead to an exaggerated immune response against components of the gut microbiome.Genetic and Environmental InfluencesMultiple genetic...
Inflammatory Bowel Disease II: Ulcerative Colitis01:20

Inflammatory Bowel Disease II: Ulcerative Colitis

Ulcerative colitis is a chronic inflammatory disorder of the colon characterized by continuous mucosal inflammation that typically begins in the rectum and extends proximally in a uniform pattern. Its pathogenesis involves a complex interplay of genetic predisposition, immune dysregulation, and environmental influences. These factors converge to impair the colon’s epithelial defenses and promote an exaggerated inflammatory response against luminal contents.Breakdown of the Mucosal BarrierA...
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents01:29

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel Disease...
Drugs for Treatment of Ulcerative Colitis in IBD01:29

Drugs for Treatment of Ulcerative Colitis in IBD

Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide generation. 
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF01:24

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab (Humira),...